HC Wainwright Issues Positive Estimate for VRDN Earnings

Key Points

• HC Wainwright has significantly raised its estimated earnings per share for Viridian Therapeutics in Q3 2025 from ($0.97) to ($0.28), maintaining a "Buy" rating with a price target of $34.00.
• Viridian's recent quarterly earnings report showed an EPS of ($1.00), aligning with consensus estimates, and a revenue increase of 4.2% year-over-year to $0.08 million.
• Analysts have varied opinions on the stock, with price targets released by institutions ranging from $30.00 to $42.00, contributing to an overall "Moderate Buy" average rating.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a report released on Thursday, August 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their previous forecast of ($0.97). HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($3.36) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($1.26) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.29) EPS, FY2026 earnings at ($4.99) EPS, FY2027 earnings at ($2.92) EPS, FY2028 earnings at ($1.73) EPS and FY2029 earnings at $0.32 EPS.

Other research analysts have also recently issued reports about the company. JMP Securities lowered their price target on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC lowered their target price on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. The Goldman Sachs Group upped their price objective on Viridian Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Oppenheimer upped their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. Finally, Royal Bank Of Canada reduced their target price on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.00.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN traded down $0.61 during midday trading on Monday, hitting $18.24. 97,898 shares of the stock traded hands, compared to its average volume of 893,792. Viridian Therapeutics has a one year low of $9.90 and a one year high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01. The firm has a market capitalization of $1.49 billion, a P/E ratio of -4.79 and a beta of 0.42. The firm has a 50-day moving average of $16.17 and a two-hundred day moving average of $15.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same quarter in the prior year, the firm posted ($0.81) earnings per share. The business's quarterly revenue was up 4.2% compared to the same quarter last year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank raised its position in Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after purchasing an additional 840 shares during the period. Foresite Capital Management VI LLC acquired a new position in Viridian Therapeutics during the 4th quarter worth $38,000. GAMMA Investing LLC boosted its position in shares of Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after acquiring an additional 8,214 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Viridian Therapeutics in the 2nd quarter valued at about $170,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.